Clinical TrialApr 16, 2026, 07:16 AM
MeiraGTx Reports Positive 3-Year Phase 1 AQUAx Clinical Data
AI Summary
MeiraGTx Holdings plc announced positive 3-year data from its Phase 1 AQUAx clinical study of AAV-hAQP1 for radiation-induced xerostomia. The treatment demonstrated safety and tolerability, with no dose-limiting toxicities or treatment-related serious adverse events. Significant improvements in Xerostomia Questionnaire scores observed at 12 months were sustained through 36 months, indicating long-term efficacy for patients.
Key Highlights
- Treatment was safe and well-tolerated over 3 years with no serious adverse events.
- 63% of participants achieved at least a 10-point XQ improvement at 12 months.
- 62% of participants maintained at least a 10-point XQ improvement at 36 months.
- Unilateral treatment showed an average 13-point XQ improvement at 12 months.
- Bilateral treatment showed an average 21-point XQ improvement at 12 months.
Price Impact
More from MGTX